Advertisement

Topics

Regenacy Pharmaceuticals Demonstrates Reversal of Chemotherapy-Induced Peripheral Neuropathy with HDAC6 Inhibitor Ricolinostat in Preclinical Model

08:00 EST 8 Mar 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
-- Results from Preclinical Studies of Selective HDAC6 Inhibitors Published Online in PAIN – Regenacy Pharmaceuticals, LLC, a clinical-stage biopharmaceutical company that is regenerating biological function by sele...

Other Sources for this Article

Regenacy:
Walter C. Ogier, 617-415-5030
President and Chief Executive Officer
or
Media:
MacDougall Biomedical Communications
Kari Watson or Casey R. Doucette, Ph.D., 781-235-3060
kwatson@macbiocom.com or cdoucette@macbiocom.com

NEXT ARTICLE

More From BioPortfolio on "Regenacy Pharmaceuticals Demonstrates Reversal of Chemotherapy-Induced Peripheral Neuropathy with HDAC6 Inhibitor Ricolinostat in Preclinical Model"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pain Disorder
Pain is a feeling (sharp or dull) triggered in the nervous system which can be transient or constant. Pain can be specific to one area of the body eg back, abdomen or chest or more general all over the body eg muscles ache from the flu. Without pain ...

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...